The global transplant diagnostics market is projected to reach USD 4.91 billion by 2023 from USD 3.44 billion in 2018, at a CAGR of 7.4%.
Factors such as increasing number of transplantation procedures, technological advancements in the field of transplant diagnostics, increasing public-private funding for target research activities, and growing burden of infectious diseases are driving the growth of the transplant diagnostics market. However, high procedural cost for next-generation sequencing (NGS) and PCR-based diagnostics assays and limited availability of reimbursements for target procedures are expected to limit the adoption of transplant diagnostics during the forecast period.
Analysis of the market developments between 2015 and 2018 reveals that several growth strategies such as product launches; expansions; acquisitions; and collaborations, partnerships, & agreements were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the transplant diagnostics market. Among these business strategies, product launches and collaborations, partnerships, & agreements were the most widely adopted growth strategies by players in the market.
Bio-Rad Laboratories, Inc. (US) dominated the global transplant diagnostics market in 2017. The company has a strong foothold in the transplant diagnostics market, with a broad range of automated instruments for antibody screening and analysis, semi-automated systems for serological assays, standalone systems, and reagents for molecular and non-molecular assay procedures, including transplant diagnostic products. During 2014–2018, Bio-Rad Laboratories, Inc. developed and commercialized several transplant diagnostic products such as Illumina Bio-Rad Single-Cell Sequencing Solution (2017), QX200 Droplet Digital PCR System (2016), IH-500 (August 2015), and BioPlex 2200 HIV Ag-Ab Assay Kit (July 2015). Moreover, Bio-Rad Laboratories continues to strengthen its R&D capabilities and distribution network to innovate transplant diagnostic products to help expand its consumer base and offer novel products. For example, in January 2016, the company partnered with Illumina, Inc. for the co-development of an NGS platform for single-cell analysis. In April 2014, Bio-Rad Laboratories signed an agreement with Premier (US) to strengthen its distribution network across North America.
- Hoffmann-La Roche Ltd. (Switzerland) held the second-largest market position in the global transplant diagnostics industry in 2017. The company is present in more than 100 countries and mainly focuses on strengthening its product portfolio. During 2014–2018, F. Hoffmann-La Roche commercialized several products, such as the cobas Plasma Separation Card (January 2018), cobas MRSA/SA test (July 2017) cobas Influenza A/B test (September 2015), cobas HBV quantitative nucleic acid test (March 2015), cobas TaqScreen MPX Test v2.0 (January 2015), and cobas 6800/8800 Systems (September 2014). Furthermore, the company continues to expand its distribution network and increase its market share, with particular emphasis on acquisitions and agreements. For example, F. Hoffmann-La Roche Ltd. signed a product distribution agreement with Sigma-Aldrich Corporation (US) in March 2015 and acquired Kappa Biosystems (US) (August 2015), Ariosa Diagnostics (December 2014), Inc. (US), and IQuum, Inc. (US) (April 2014).
